Galmed Pharmaceuticals CEO Letter: Strong Cash Position and Strategic Expansion
Galmed Pharmaceuticals issued a Letter to Shareholders from Allen Baharaff, Chief Executive Officer. "Over the past year, we have successfully expanded our therapeutic focus beyond liver disease, generating compelling new data that supports a broader clinical development path for Aramchol in oncology and cardiometabolic indications... My message to investors is clear: Galmed is well-capitalized, scientifically advancing on multiple fronts, and positioned for meaningful growth opportunities. 1. Strong Cash Position and Prudent Financial Stewardship. Galmed ended the third quarter of 2025 with approximately $19.2 million in cash and practically zero debt on our balance sheet... 2. Significant Clinical Advancements. Aramchol for MASH and liver fibrosis... Aramchol for Gastrointestinal oncology indications... Expansion Potential Beyond MASH and Oncology... Looking Ahead: In summary, I want to emphasize the following: Galmed remains financially strong, with sufficient resources to support our current strategic and clinical plans. Our scientific progress has been exceptional, with multiple breakthroughs validating and expanding the potential of Aramchol across high-value therapeutic areas. We are committed to short and long-term value creation, grounded in disciplined execution, scientific innovation, and responsible financial stewardship. Throughout this process, we aim to maintain transparency, careful capital allocation, and clear communication with our shareholders."
Get Free Real-Time Notifications for Any Stock
Analyst Views on GLMD
About GLMD
About the author
Galmed Pharmaceuticals to Initiate Phase 1/2 Trial of Aramchol and Regorafenib in 2026
- Clinical Trial Launch: Galmed Pharmaceuticals announced the initiation of a Phase 1/2 clinical trial for the combination of Aramchol and Regorafenib in 2026, aimed at enhancing treatment efficacy for hepatocellular carcinoma and other GI cancers, marking a significant advancement in the company's liver disease treatment efforts.
- Scientific Rationale Strengthened: Research indicates that Aramchol significantly enhances Bayer's Regorafenib efficacy in GI cancer models through SCD1 inhibition, providing a solid scientific foundation for the upcoming clinical trial.
- Investor Value Enhancement: Positive outcomes from the clinical trial could lay the groundwork for expanding Galmed's oncology pipeline, potentially attracting more investor interest and increasing the company's overall market value.
- Industry Recognition: The acceptance of Galmed's latest research findings at the HEP-DART 2025 meeting underscores the significance of its work in liver disease treatment, further enhancing the company's competitive position in the market.
Galimedix Reports Excellent Phase 1 Results for GAL-101 with No Adverse Events
- Clinical Trial Success: Galimedix presented Phase 1 study results for GAL-101 at CTAD 2025, involving approximately 100 healthy volunteers, demonstrating excellent safety and tolerability with no dose-limiting adverse events, indicating the drug's potential in Alzheimer's treatment.
- Drug Penetration Capability: GAL-101 confirmed effective blood-brain barrier penetration with lumbar CSF concentrations after multiple doses, supporting a once-daily dosing regimen for future trials, which may enhance patient adherence to treatment.
- Future Research Planning: Following positive Phase 1 results, Galimedix is planning a Phase 2 proof-of-concept study in Alzheimer's disease, expected to include cognitive functional endpoints and biomarkers to capture early signs of cognitive improvement.
- Technological Innovation: As a small molecule targeting misfolded amyloid beta monomers to prevent toxic aggregate formation, GAL-101 shows broad application prospects in treating Alzheimer's disease, dry age-related macular degeneration, and glaucoma.
